CytomX Therapeutics (CTMX) Tops Q2 EPS by 6c, Misses on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to CytomX Therapeutics (CTMX) Tops Q2 EPS by 6c, Misses on Revenue

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 4:10 PM EDT

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -

- CX-2051 Phase 1 dose expansions on track for data update in Q1 2026.
Phase 2 study initiation in CRC anticipated 1H 2026 -

- Combination dose escalation initiated of CX-801 masked interferon alpha-2b with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma -

- Completed $100 million underwritten offering of common stock -

-... More